Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 15, No. 2, 2016, pp. 313-317
Bioline Code: pr16041
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 15, No. 2, 2016, pp. 313-317
© Copyright 2016 - Tropical Journal of Pharmaceutical Research
Epigallocatechin-3-gallate Promotes Osteoblastic Activity in Human Osteoblast-like Cells|
Peng, Yuewen; Yu, Bin & Liu, Fang
Purpose: To investigate the effect of epigallocatechin-3-gallate (EGCG) on bone metabolism and
Methods: MG-63 human osteoblast-like cells were treated with varied concentrations of EGCG.
Alkaline phosphatase (ALP) activity and matrix mineralization assays were carried out on the treated
and untreated MG-63 human osteoblast-like cells. Beta-catenin mRNA level was determined by
quantitative real-time polymerase chain reaction (q-PCR).
Results: The results showed that EGCG treatment significantly increased ALP and mineralization
activities at concentrations of 15 and 30 μM, in a dose-dependent manner. Furthermore, EGCG
treatment significantly increased beta-catenin mRNA expression by 70.7 ± 11.0 and 126.7 ± 35.1 %,
respectively, at EGCG concentration of 15 and 30 μM. In addition, the stimulating effect of EGCG
treatment on ALP activity was abolished by co-treatment with ICI 182,780, an antagonist of estrogen
receptor (ER). Again, the increase in beta-catenin MRNA, when treated with EGCG, was inhibited by
co-treatment with ICI 182,780.
Conclusion: EGCG promotes osteoblastic activity in human osteoblast-like cells, by Wnt signaling
through estrogen receptor (ER) pathway.
Epigallocatechin-3-gallate; Osteoporosis; Osteoclast; Proliferation; Estrogen receptor
Alternative site location: http://www.tjpr.org